Geron Corporation (NASDAQ:GERN) is among the 13 Best American Penny Stocks to Invest In. TD Cowen analyst Tara Bancroft lowered GERN’s price target from $4 to $3 ahead of the company’s Q4 results on February 25. GERN also revealed its 2026 financial guidance, expecting RYTELO net product revenue to be $220-240 million.

In 2026, Geron (GERN) aims to grow RYTELO in the US, expand into LR-MDS markets, and advance its Phase 3 IMpactMF trial. As a biopharmaceutical company, GERN focuses on developing therapies for blood cancer patients. While GERN shows investment potential, consider AI stocks for greater upside and lower risk.

For more insights on AI stocks and investment opportunities, visit Insider Monkey. GERN’s 2026 goals include growing RYTELO commercially, exploring new markets, and advancing clinical trials. This commercial-stage biopharmaceutical company aims to develop therapies for blood cancer patients.

Read more at Yahoo Finance: Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT